The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s July 18th 2013 Stock Forecast titled, Algorithmic Trading : 23.93% Gain in 3 Months. The "I Know First Average" return was 8.53% versus the S&P 500’s return of 5.96% over the same time period.
The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s July 12th 2013 Stock Forecast titled, Best Aggressive Stocks Based On Algorithms: 158.27% Gain in 1 Year. The "I Know First Average" return was 45.09% versus the S&P 500’s return of 17.47% over the same time period.
The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s July 9th 2014 Stock Forecast titled, Best Investments Based on Algorithms: 55.34% Gain in 3 Months. The "I Know First Average" return was 15.43% versus the S&P 500’s return of 7.79% over the same time period.
Cliffs Natural Resources Inc. is an international mining and natural resources company. The Company is an iron ore producer and a producer of metallurgical coal. The stock is down almost 9% in the past week. Casablanca Capital, a firm that owns over 5% of Cliffs Natural Resources stocks, is lobbying fiercely for a shakeup in management, claiming that it’s destroying the company. Casablanca released a note to shareholders on July 10th calling for the removal of six of the company’s directors at the annual shareholders meeting later this month. The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s July 5th 2014 Stock Forecast titled, Best Aggressive Stocks Based On Algorithms: 166.90% Gain in 1 Year. The "I Know First Average" return was 62.15% versus the S&P 500’s return of 22.19% over the same time period.
The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s June 1st 2014 Stock Forecast titled, Best Investments Based on Algorithms: 18.68% Gain in 30 days. The "I Know First Average" return was 6.98% versus the S&P 500’s return of 2.59% over the same time period.
For fiscal year 2014, revenues were up 14% year over year to $2.2 billion, beating the Zacks Consensus Estimate of $2.15 billion. However, earnings came in at $2.10 per American Depository Share (ADS), short of Zacks Consensus Estimate of $2.18. Research and Development (R&D) expenses increased 62% to $207 million during the fiscal year. In addition, Dr. Reddy made 13 filings in the US, and on June 27th, Dr. Reddy announced it had launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg, and 60 mg, the generic equivalent of Cymbalta. Cymbalta is one of the leading prescription drugs used to treat depression and anxiety, as it had sales in the U.S. of roughly $5.04 billion for the 12 months ending in April 2014, according to IMS Health.
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.